“BioMarin Pharmaceutical’s leadership outlined a refreshed corporate strategy at the recent TD Cowen Healthcare Conference, focusing on business development, integration of recent acquisitions, and robust operational efficiencies. The company reaffirmed its target of approximately 40% non-GAAP operating margin in 2026 (excluding Amicus impact), while addressing emerging competition for its key growth driver Voxzogo and emphasizing long-term durability through global expansion and safety advantages.”
BioMarin Outlines Strategic Refresh Amid Growth Drivers and Competitive Pressures
At the TD Cowen 46th Annual Healthcare Conference, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) executives, led by President and CEO Alexander Hardy, provided a comprehensive update on the company’s direction following a two-year strategic overhaul. Hardy highlighted the evolution since taking the helm, shifting emphasis toward scaled infrastructure for rare diseases, proactive business development, and disciplined capital allocation to sustain long-term value creation.
Central to the discussion was the company’s completed $500 million cost transformation program, which has streamlined operations and positioned BioMarin for enhanced profitability. This initiative contributed to strong underlying financial performance in 2025, where total revenues reached a record $3.2 billion, up 13% year-over-year. Growth was broad-based, with enzyme therapies advancing 9% and Voxzogo surging 26% to $927 million for the full year. In the fourth quarter alone, revenues climbed 17% to $875 million, driven by 31% growth in Voxzogo and 13% in enzyme therapies.
Looking ahead, BioMarin guided for 2026 total revenues of $3.325 billion to $3.425 billion (excluding Amicus contributions), with Voxzogo projected at $975 million to $1.025 billion and enzyme therapies at $2.225 billion to $2.275 billion. Non-GAAP diluted EPS is expected in the range of $4.95 to $5.15, reflecting continued momentum.
A key highlight was the reaffirmed goal of achieving approximately 40% non-GAAP operating margin in 2026 on an organic basis, excluding the impact of the Amicus transaction. This target underscores the success of cost discipline and operational leverage, as the company transitions toward higher-margin contributions from its core portfolio.
Voxzogo Faces Competition but Maintains Strong Positioning
Voxzogo (vosoritide), the once-daily injectable therapy for achondroplasia, remains BioMarin’s primary growth engine and the focal point of competitive dynamics. The product generated significant demand in 2025, with 26% full-year revenue growth fueled by deeper penetration across 55 commercial markets and increasing patient initiations, particularly in regions outside the U.S.
Executives addressed recent competitive developments head-on, noting that a new competitor received FDA approval recently. However, they expressed confidence in Voxzogo’s competitive stance, emphasizing its established long-term durability, safety profile, and real-world evidence. Switching patients is expected to be complex and gradual due to these factors, limiting rapid erosion.
Importantly, only about 25% of Voxzogo revenues stem from the U.S. market, where competition narratives dominate headlines. The remaining 75% comes from international markets, where BioMarin continues to deepen penetration in existing territories and launch into new countries. Growth in the under-2 age group—where Voxzogo is the only approved therapy—provides additional tailwinds. Executives indicated that outperforming expectations could stem from accelerated international expansion and sustained uptake in younger patients.
The company is also advancing its CANOPY clinical program to expand Voxzogo into five additional indications, targeting a much larger total addressable patient population and positioning the product as a potential franchise across multiple skeletal conditions.
Acquisitions Bolster Portfolio and Diversify Growth
BioMarin has pursued strategic acquisitions to enhance its rare disease capabilities and offset potential pressures on Voxzogo. Recent integrations include Inozyme and the pending Amicus transaction, which adds two commercial enzyme therapies—Galafold and Pombiliti + Opfolda—to the portfolio. These assets are expected to strengthen the enzyme therapies business unit, driving diversified revenue streams.
The Amicus deal is anticipated to be slightly dilutive in 2026 but accretive within the first 12 months post-close and substantially accretive by 2027. This approach reflects a deliberate strategy to build scale in rare diseases through business development, complementing organic growth.
Portfolio Optimization and Other Updates
In a related move, BioMarin has pursued divestment options for Roctavian, its gene therapy for hemophilia A, following a voluntary market withdrawal and associated charges in 2025. This decision allows sharper focus on higher-priority areas like enzyme therapies and skeletal conditions.
Palynziq, part of the enzyme therapies lineup, demonstrated robust performance with 22% growth in the prior year and continued strong quarterly increases, highlighting the durability of this segment.
Overall, the conference presentation reinforced BioMarin’s commitment to innovation, efficiency, and strategic positioning in rare diseases, balancing near-term competitive challenges with long-term growth opportunities through portfolio expansion and operational excellence.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial recommendations, or a solicitation to buy or sell securities. Investors should conduct their own research and consult with qualified professionals before making decisions.